Rel-(3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)-2,5-Pyrrolidinedione structure
|
Common Name | Rel-(3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)-2,5-Pyrrolidinedione | ||
|---|---|---|---|---|
| CAS Number | 905853-99-8 | Molecular Weight | 369.42 | |
| Density | 1.49±0.1 g/cm3(Predicted) | Boiling Point | 715.9±60.0 °C(Predicted) | |
| Molecular Formula | C23H19N3O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 386.8±32.9 °C | |
Use of Rel-(3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)-2,5-Pyrrolidinedione(rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC)[1]. |
| Name | 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-rel- |
|---|---|
| Synonym | More Synonyms |
| Description | (rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC)[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.49±0.1 g/cm3(Predicted) |
|---|---|
| Boiling Point | 715.9±60.0 °C(Predicted) |
| Molecular Formula | C23H19N3O2 |
| Molecular Weight | 369.42 |
| Flash Point | 386.8±32.9 °C |
| Exact Mass | 369.147736 |
| LogP | 3.26 |
| Vapour Pressure | 0.0±2.3 mmHg at 25°C |
| Index of Refraction | 1.797 |
| Storage condition | 2-8°C |
| (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione |
| (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione |
| 9326 |
| PJ4H73IL17 |
| (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]chinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidin-2,5-dion |
| ARQ 197 |
| MFCD11977597 |
| 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)- |
| Tivantinib |
| ARQ-197 |